CRISPR Therapeutics AG (CRSP) Other financing activities (2017 - 2026)

CRISPR Therapeutics AG has reported Other financing activities for 10 years, with the latest figure at $6.2 million in Q1 2026.

• Quarterly Other financing activities rose 197.2% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.0 million (up 291.85% YoY) and the FY2025 annual result came in at $27.9 million, down 10.72% from the prior year.
• Other financing activities rose to $6.2 million in Q1 2026 per CRSP's latest filing, from $4.9 million in the prior quarter.
• Over five years, Other financing activities peaked at $25.2 million in Q1 2024 and troughed at $546000.0 in Q2 2024.
• A 5-year average of $7.8 million and a median of $5.4 million in 2023 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2024 and 2025: Other financing activities slumped 96.74% in 2024, then jumped 413.09% in 2025.
• Over 5 years, Other financing activities stood at $2.5 million in 2022, then surged by 150.93% to $6.2 million in 2023, then sank by 69.17% to $1.9 million in 2024, then surged by 156.81% to $4.9 million in 2025, then increased by 25.09% to $6.2 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $6.2 million, $4.9 million, and $18.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.